Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 74,55€(+159,94%). Der Median liegt bei 74,55€(+159,94%).
Kaufen | 1 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025
We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2 2025. The company has a decent balance sheet, with roughly $40.3 million in cash. It may need to raise capital by mid-2026 or earlier as R&D expenses increase.» Mehr auf seekingalpha.com
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC (“Scienture”), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. (“Kindeva”)), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.» Mehr auf globenewswire.com
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101
Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence Epilepsy and DEE could have data released by 2026, potentially establishing it as a best-in-class 5-HT2C receptor agonist. The company has a $35 million private placement, extending its cash runway beyond 2026 and supporting its pipeline, including drugs for depression, PTSD, and anxiety.» Mehr auf seekingalpha.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | - |
Nettoeinkommen | 33,22k | 102,89% |
EBITDA | −1,07 Mio | 5,46% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 202,09 Mio€ |
Anzahl Aktien | 7,04 Mio |
52 Wochen-Hoch/Tief | 69,31€ - 0,82€ |
Dividenden | Nein |
Beta | 1,02 |
KGV (PE Ratio) | −261,80 |
KGWV (PEG Ratio) | −4,01 |
KBV (PB Ratio) | 4,84 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Bright Minds Biosciences Inc. ist ein präklinisches Biowissenschaftsunternehmen, das 5-HT-Medikamente (Serotonin) entwickelt, um das Leben von Patienten mit schweren und lebensverändernden Krankheiten zu verbessern. Sein Portfolio an selektiven 5-HT-Rezeptor-Agonisten umfasst 5-HT2C, 5-HT2A und 5-HT2C/A für die Behandlung von Epilepsie, Schmerzen und Neuropsychiatrie. Das Unternehmen arbeitet mit den National Institutes of Health für die Behandlung von Epilepsie, der University of Texas Medical Branch zur Behandlung von Impulskontrollstörungen wie Binge Eating und dem Medical College of Wisconsin zusammen. Das Unternehmen wurde 2019 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.
Name | BRIGHT MINDS BIOSCIENCES |
CEO | Ian McDonald |
Sitz | Vancouver, bc Kanada |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 0 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | DRUG |
Assets entdecken
Shareholder von BRIGHT MINDS BIOSCIENCES investieren auch in folgende Assets